March 28, 2018 – 2 PM ET

What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice?

What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to have an adverse event?

The convergence of AI and big data enable the ability to measure, predict and personalize care in a way previously not possible. Join Dr. Richard Gliklich, CEO of OM1, as he explores different ways you can use big data and AI to advance drug development and commercialization, including:

  • Identifying under-diagnosed patients
  • Identifying likely responders in trials and in practice
  • Predicting which patients have the most potential for adverse events
  • Comparing and predicting treatment outcomes across different populations